Billaud M - Search Results

1

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.

Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Moccia M, et al. Among authors: billaud m. PLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015. PLoS One. 2015. PMID: 26046350 Free PMC article.

2

RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block.

Alfano L, Guida T, Provitera L, Vecchio G, Billaud M, Santoro M, Carlomagno F. Alfano L, et al. Among authors: billaud m. J Clin Endocrinol Metab. 2010 Jul;95(7):3552-7. doi: 10.1210/jc.2009-2315. Epub 2010 May 5. J Clin Endocrinol Metab. 2010. PMID: 20444924

3

Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.

De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M. De Falco V, et al. Among authors: billaud m. J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22. J Clin Endocrinol Metab. 2013. PMID: 23526464

4

Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase.

Salvatore G, Nagata S, Billaud M, Santoro M, Vecchio G, Pastan I. Salvatore G, et al. Among authors: billaud m. Biochem Biophys Res Commun. 2002 Jun 21;294(4):813-7. doi: 10.1016/S0006-291X(02)00560-0. Biochem Biophys Res Commun. 2002. PMID: 12061779

5

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.

Carlomagno F, Guida T, Anaganti S, Vecchio G, Fusco A, Ryan AJ, Billaud M, Santoro M. Carlomagno F, et al. Among authors: billaud m. Oncogene. 2004 Aug 12;23(36):6056-63. doi: 10.1038/sj.onc.1207810. Oncogene. 2004. PMID: 15184865

6

Molecular mechanisms of RET activation in human neoplasia.

Santoro M, Carlomagno F, Melillo RM, Billaud M, Vecchio G, Fusco A. Santoro M, et al. Among authors: billaud m. J Endocrinol Invest. 1999 Nov;22(10):811-9. doi: 10.1007/BF03343650. J Endocrinol Invest. 1999. PMID: 10614534 Review. No abstract available.

7

Is Co-option a prevailing mechanism during cancer progression?

Billaud M, Santoro M. Billaud M, et al. Cancer Res. 2011 Nov 1;71(21):6572-5. doi: 10.1158/0008-5472.CAN-11-2158. Epub 2011 Oct 25. Cancer Res. 2011. PMID: 22028321 Review.

8

Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.

De Vita G, Melillo RM, Carlomagno F, Visconti R, Castellone MD, Bellacosa A, Billaud M, Fusco A, Tsichlis PN, Santoro M. De Vita G, et al. Among authors: billaud m. Cancer Res. 2000 Jul 15;60(14):3727-31. Cancer Res. 2000. PMID: 10919641

9

The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret.

Melillo RM, Carlomagno F, De Vita G, Formisano P, Vecchio G, Fusco A, Billaud M, Santoro M. Melillo RM, et al. Among authors: billaud m. Oncogene. 2001 Jan 11;20(2):209-18. doi: 10.1038/sj.onc.1204049. Oncogene. 2001. PMID: 11313948

10

Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade.

Melillo RM, Santoro M, Ong SH, Billaud M, Fusco A, Hadari YR, Schlessinger J, Lax I. Melillo RM, et al. Among authors: billaud m. Mol Cell Biol. 2001 Jul;21(13):4177-87. doi: 10.1128/MCB.21.13.4177-4187.2001. Mol Cell Biol. 2001. PMID: 11390647 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

153 results

Search Page

Filters